Astonea Labs Share Price
268.00-2.00 (-0.74%)
+52.10% past 1 Year
Astonea Labs specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products. These include antibiotic drugs, anti-cold medications, antihistamines, and drugs for diabetes, cardiovascular diseases,
Corporate filings & documents
Announcements
Approval of Alteration in Object Clause of the Memorandum of Association ("MOA") of the Company
1 week agoApproval of Alteration in Object Clause of the Memorandum of Association ("MOA") of the Company
1 week agoRe-appointment of Ms. Pooja Singh as Director of the Company
1 week agoRe-appointment of Ms. Pooja Singh as Director of the Company
1 week agoScrutinizers Reports and Voting Results of the 9th Annual General Meeting ("AGM") of the Company held on 21st August 2026
1 week agoScrutinizers Reports and Voting Results of the 9th Annual General Meeting ("AGM") of the Company held on 21st August 2026
1 week agoProceedings of 9th Annual General Meeting ("AGM") of the Company for the financial year 2025-26 held on 21st August 2026
1 week agoProceedings of 9th Annual General Meeting ("AGM") of the Company for the financial year 2025-26 held on 21st August 2026
1 week agoIntimation regarding Newspaper Publication of Notice of 9th Annual General Meeting ("AGM") of the Company.
1 month agoIntimation regarding Newspaper Publication of Notice of 9th Annual General Meeting ("AGM") of the Company.
1 month agoAnnual Report of the Company for the Financial year 2025-26.
1 month agoAnnual Report of the Company for the Financial year 2025-26.
1 month agoPlease find enclosed herewith an attached Notice of 9th Annual General Meeting ("AGM") of the Company for the Financial Year 2025-26 scheduled to be held on Friday 21st August 2026.
1 month agoPlease find enclosed herewith an attached Notice of 9th Annual General Meeting ("AGM") of the Company for the Financial Year 2025-26 scheduled to be held on Friday 21st August 2026.
1 month agoIntimation under Regulation 30- Revision in Re-appointment of Tax Auditor under Income Tax Act 2025
1 month agoIntimation under Regulation 30- Revision in Re-appointment of Tax Auditor under Income Tax Act 2025
1 month agoAudited Consolidated Financial Results for the Half year and year ended 31.03.2026
1 month agoAudited Consolidated Financial Results for the Half year and year ended 31.03.2026
1 month agoOutcome of the Board Meeting held on 24th July 2026
1 month agoOutcome of the Board Meeting held on 24th July 2026
1 month agoAstonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 inter alia to consider and approve Audited Consolidated Financial Results for the financial year ended 31.03.2026 along with other agenda items.
1 month agoAstonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 inter alia to consider and approve Audited Consolidated Financial Results for the financial year ended 31.03.2026 along with other agenda items.
1 month agoIntimation under Regulation 30 of SEBI(LODR)Regulations 2015 - Execution and Registration of Sale Deed for Sale of Immovable Properties located in Gurugram Haryana.
1 month agoIntimation under Regulation 30 of SEBI(LODR)Regulations 2015 - Execution and Registration of Sale Deed for Sale of Immovable Properties located in Gurugram Haryana.
1 month agoIntimation under Regulation 30 regarding successful completion of Regulatory Inspection of Manufacturing Facility by Supreme Board of Drugs and Medical Appliances (SBDMA) Ministry of Health and Population Republic of Yemen.
1 month agoIntimation under Regulation 30 regarding successful completion of Regulatory Inspection of Manufacturing Facility by Supreme Board of Drugs and Medical Appliances (SBDMA) Ministry of Health and Population Republic of Yemen.
1 month agoPlease find enclosed herewith the Certificate under Reg. 74(5) of the SEBI (Depositories and Participants) Regulations 2018 pertaining to the quarter ended 30.06.2026.
1 month agoPlease find enclosed herewith the Certificate under Reg. 74(5) of the SEBI (Depositories and Participants) Regulations 2018 pertaining to the quarter ended 30.06.2026.
1 month agoPlease find enclosed the Revised Financial Results along with the additional documents sought by BSE through its email dated 19th June 2026
2 months agoPlease find enclosed the Revised Financial Results along with the additional documents sought by BSE through its email dated 19th June 2026
2 months agoSubmission of Half-Yearly Disclosure on Related Party Transactions for the period ended 31.03.2026
3 months agoSubmission of Half-Yearly Disclosure on Related Party Transactions for the period ended 31.03.2026
3 months agoStatement of Deviation & Variation for the half year ended 31.03.2026
3 months agoStatement of Deviation & Variation for the half year ended 31.03.2026
3 months agoIntimation under Regulation 30- Re-appointment of Tax Auditor
3 months agoIntimation under Regulation 30- Re-appointment of Cost Auditor
3 months agoIntimation under Regulation 30- Re-appointment of Cost Auditor
3 months agoIntimation under Regulation 30- Re-appointment of Secretarial Auditor
3 months agoIntimation under Regulation 30- Re-appointment of Secretarial Auditor
3 months agoAudited Standalone Financial Results for the half year and year ended 31.03.2026
3 months agoOutcome of the Board Meeting held on 30th May 2026
3 months agoOutcome of the Board Meeting held on 30th May 2026
3 months agoAstonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Audited Financial Results (Standalone and Consolidated) for the half year and year ended on 31st March 2026 alongwith other agenda items.
3 months agoAstonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Audited Financial Results (Standalone and Consolidated) for the half year and year ended on 31st March 2026 alongwith other agenda items.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Astonea Labs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24304CH2017PLC041482</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>23.96</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKIT KAPOOR <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: SUMIT KUMAR <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 29/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoIntimation under Regulation 30 of SEBI LODR (Regulations) 2015 regarding Fire Incident at premises of Companys Manufacturing Facility
4 months agoPlease find enclosed herewith a statement on redressal of Investor Grievances for the quarter ended 31.03.2026
4 months agoPlease find enclosed herewith the Certificate under Reg. 74 (5) of SEBI (Depositories & Participants) Regulations 2018 pertaining to the quarter ended 31.03.2026.
4 months agoPlease find enclosed herewith the Certificate under Reg. 74 (5) of SEBI (Depositories & Participants) Regulations 2018 pertaining to the quarter ended 31.03.2026.
4 months agoAcquisition of Equity Stake in Damaira Pharmaceuticals Private Limited
5 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Sco 321-322 Basement Sector 35 B Chandigarh Union Territory PIN: 160022 Tel No: 9012018814 Fax No: NULL Email: [email protected] Internet: www.astonea.org
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Ankit Kapoor, Company Secretary & Compliance Officer
Ashish Gulati, Managing Director
Vikrant, Non Executive Director
Pooja Singh, Non Executive Director
Pardeep Dalal, Non Executive Director
Arun Kumar Tripathi, Non Executive Director
Karan Vir Bindra, Non Executive Independent Director
Salina Chalana, Non Executive Independent Director
Akash Arora, Non Executive Independent Director
Details
BSE 544409
NSE NULL
ISIN INE0TG901011